




CollPlant

Corporate Presentation

Nasdaq: CLGN

2026



Forward-Looking Statements

The statements made in this presentation speak only as of the date stated herein, and subsequent events and developments may cause our expectations and beliefs to change. Unless otherwise required by applicable securities laws, we do not intend, nor do we undertake any obligation, to update or revise any forward-looking statements contained in this presentation to reflect subsequent information, events, results or circumstances or otherwise. While we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law.

Certain statements in this presentation constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and are expected to be affected by a variety of risks and factors that are beyond our control. Risks and uncertainties for our company include, but are not limited to: the Company's history of significant losses and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based BioInk and products for medical aesthetics; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInk and medical aesthetics products including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. Many of these factors that will determine actual results are beyond our ability to control or predict. For a discussion of the factors that may cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied in such forward-looking statements, see the "Risk Factors" section of included in our most recently filed Annual Report on Form 20-F. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.

About CollPlant

A regenerative medicine company developing innovative technologies and products for medical aesthetics, tissue regeneration, and organ manufacturing

The Company's products and candidates are based on rhCollagen that is produced in genetically engineered tobacco plants


Clinically validated platform with two CE-marked products

Collagen is an Essential Component of the Human Body

25% to 35%
of the whole-body protein content

The main structural protein in the
extracellular matrix found in the body's
organs and various connective tissues*

Ideal scaffolding molecule
for regenerative medicine




Our Technology Platform Produces Human Collagen in Plants at Mass-Scale



Human Collagen Platform

Clear advantages over tissue-extracted (animal-derived) collagen



Human-identical collagen

Xeno-free (plant-derived)

Tunable properties

High consistency

Biologically active (non-immunogenic, ECM-mimetic)

Our Product Pipeline

Product	Use	Preclinical	Clinical	Commercial	Status/Partner
Regenerative Aesthetic					
Injectable tissue fillers	Dermal/soft tissue fillers				
Photocurable filler	Dermal/soft tissue fillers				
Regenerative medicine					
Breast implants	Breast reconstruction and augmentation				
Soft Tissue Repair & BioInks	Tissues, organs, drug discovery and tissue modelling				

Dermal/Soft Tissue Fillers



Dermal Fillers: Market Overview

~5.3M

Hyaluronic Acid procedures in 2023 in the US¹

\$6.3B, 10.3% CAGR


Global dermal filler market, 2023, CAGR 2023-2033²

\$100-\$250/unit

Cost per syringe³



1. The American Society of Plastic Surgeons®, 2023 Procedural Stats Release
2. <https://finance.yahoo.com/news/dermal-filler-market-reach-16-151000525.html>
3. www.medicalspax.com/iuvederm-hydrate
4. www.medicalspax.com/buy-juvederm-ultra-plus-xc



■ Polymethyl methacrylate microspheres

■ Fat

■ Polylactic acid

■ Hyaluronic acid

■ Calcium Hydroxylapatite

■ PRP

From Volume to Regenerative Structural Fillers



**Programmable
Structural
Regeneration**

**A New Category
in Aesthetics**

HA-rhCollagen: A Regenerative Filler


HA (volumization)

Regenerative Filler

Immediate volumization
Supports tissue regeneration
High biocompatibility

rhCollagen (biology)

Regenerative HA-rhCollagen Filler Platform



- **Hybrid HA + rhCollagen Technology**

Combines the immediate volumizing effect of hyaluronic acid with the regenerative bioactivity of recombinant human collagen for natural-looking aesthetic outcomes.

- **Designed for Natural Tissue Integration**

Designed to promote natural tissue integration and improved skin quality beyond traditional volumizing fillers.

- **Versatile HA-rhCollagen Platform**

Designed to support a broad range of aesthetic applications, from skin boosting and fine lines to deep folds and mid-face volumization.


HA-rhCollagen Photocurable Regenerative Dermal Filler



Inject → Shape → Light → Fix

Injection


rhCollagen-HA formulation



Sculpting



Photocuring in-situ



Filler Features:

Structural scaffold formation

Precise contouring

Tissue integration

Introducing the Photocurable rhCollagen Platform



Light-activated *in-situ*
Structural fixation



High G' scaffold for
Contouring control



Human-identical rhCollagen
For biological integration



A Photocurable Dermal Filler would be an **all-in-one innovation:**

Flexibility

compliance with facial expression

Moldability


precise contour definition

Cohesivity

maintains the defined shape

Elasticity

Recovers original shape
(aligned with facial expression)



KOL Testimonial*

Dr. Jason Bloom MD, FACS

BLOOM FACIAL PLASTIC SURGERY

- “The first injectable moldable implant”
- “Provides cohesivity and structural support that far exceeds anything in the market”
- “A customizable implant that can be implanted in the office with a minimally invasive procedure.”
- “Huge advance in the dermal and soft tissue market, and facial plastic surgery”
- “Long lasting results”
- “Game changer for facial plastic surgery and soft tissue filler”

* Following evaluation of the Photocurable Dermal Filler



Use is experimental only at physician's discretion.
CollPlant's photocurable filler is not yet FDA-approved.



KOL Testimonial

Dr. Sachin M. Shridharani, MD, FACS
Director - LUXURGERY (New York, NY)

- “It changes the overall approach of long-lasting facial sculpting”
- “Transforming an injectable filler into a solid-like gel”
- “It forms an elastic, cohesive and integrated piece”
- “Increased G’, cohesivity, longevity, tissue regeneration”
- “Compatible for off-the-face areas”
- “Nothing like this is observed with available fillers”

* Following evaluation of the Photocurable Dermal Filler



Use is experimental only at physician's discretion.
CollPlant's photocurable filler is not yet FDA-approved.



GLP-1 Opportunity

A new aesthetic challenge driven by metabolic weight loss

- Rapid fat pad deflation
- Loss of facial structural support
- Unmet need beyond conventional fillers



Commercial Product Portfolio



rhCollagen BioInk components



rhCollagen-based Bioink Platform for Biofabrication

Animal-free: excellent safety profile, non immunogenic


Optimal rheology at room temperature

Cytocompatible biofunctional

Compatible with major printing technologies

Mass production. consistency, robustness

High homogeneity reproducibility




Collink-3D 90

Collink-3D 50L

Collink-3D 50

3D Bioprinting Represents a Wide Range of Development Opportunities



3D-bioprinted Regenerative Breast Implants





Revolutionary Option: The Ability to Regenerate Breast Tissue

No regenerative breast implant exists

Safety issues exist with silicone breast implants



Breast Implant Market Overview

\$3.0B Market

worldwide (2024)¹

\$ 5-10K Cost


per full procedure in US²

~2,200,000


Breast implant procedures WW (2022)³



1. www.imarcgroup.com/breast-implant-market
2. www.webmd.com/beauty/cosmetic-procedures-breast-augmentation#1
3. <https://finance.yahoo.com/news/global-breast-implants-market-report-133700143.html>




CollPlant's 3D Bioprinted Breast Implants



Our Solutions For Advancing Medicine Without Animals

FDA “New Approach Methodologies” (NAMs):

Designed to improve drug safety and accelerate the evaluation process while reducing animal testing



rhCollagen-based BioInks:

Collink.3D™ portfolio of BioInk products can be used in a wide variety of non-animal testing applications (tissue-on-a-chip or organ-on-a-chip systems)

Mayo Clinic Devises *First-Ever Skin-on-a Chip*:

Published in the *Archives of Dermatological Research* – the first fully humanized 3D bioprinted skin model using CollPlant’s rhCollagen. The model has broad potential as an alternative to animal testing with potential applications in cosmetic and pharmaceutical testing, disease modeling and drug development. (10/16/2025)

Matrigel Head-to-Head Study Conducted by Levenberg Lab at Technion – Israel Institute of Technology - **Collink.3D** demonstrated enhanced mechanical strength, elasticity and stability in a head-to-head study against Matrigel®, a gold standard biomaterial used for cell culture, disease modeling and drug discovery. (10/20/2025)

Computational Modeling and Simulation

(CM&S) Methodologies: Enables the precise prediction of the mechanical behavior of the regenerative breast implant product candidate in the body to assist with its development.



Seasoned Management Team with Engineering, Pharmaceutical, Device and Life Sciences Experience



Yehiel Tal
CEO

Regentis Biomaterials
ProChon Biotech
Kulicke & Soffa Industries



Eran Rotem
Deputy CEO & CFO

Tefron, CFO (NYSE, TASE)
Healthcare Tech., CFO
(Nasdaq) & Gamida, E&Y



Jasmine Seror, PhD
VP Product Development

Weizmann Institute of Science



Philippe Bensimon
PharmD VP RA/QA/CA

Maquet Getinge
3M Medical



Bar Abelis
VP Legal Affairs

Goldfarb Gross Seligman



Oren Fahimipoor
VP Operations

Omrix Biopharmaceuticals (J&J)
Teva Pharmaceutical Industries Ltd

Investment Summary



Proprietary, Plant-Based rhCollagen Technology Platform

The only commercially scalable platform capable of producing recombinant human collagen without reliance on animal-derived tissue



Targeting Large, High-Growth Markets

Advancing innovative regenerative medical aesthetic solutions based on rhCollagen technology, including next-generation soft tissue fillers designed to combine volumization, structural support, and tissue regeneration



Broadly Applicable and Clinically Validated Technology

A differentiated regenerative medicine platform with clear advantages over animal-derived collagen. Enables innovative products and expanded therapeutic applications



Advanced Biofabrication Capabilities

Combining rhCollagen with cutting-edge biomaterials and biofabrication technologies, including 3D bioprinting, to enable the development of functional tissues and regenerative implants



Experienced Leadership Team

Highly experienced management with deep expertise across bioengineering, biomaterials, regenerative medicine, pharmaceuticals, medical devices, and commercialization



Sustainable In-House Manufacturing Infrastructure

Integrated cGMP manufacturing capabilities supported by proprietary, environmentally responsible production processes designed for scalability, consistency, and commercial supply

